Dalpiciclib Breast Cancer Survival – HR+/HER2- Patients
Dalpiciclib Plus Endocrine Therapy Shows Significant Advancement in Invasive Disease-Free Survival for Early Breast Cancer
Table of Contents
New findings from the Phase III DAWNA-A trial highlight the efficacy of dalpiciclib in combination with endocrine therapy (ET) for patients with HR+/HER2- early breast cancer.
Promising Results in Adjuvant Treatment
In a significant advancement for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer, the Phase III DAWNA-A trial has demonstrated that the addition of dalpiciclib to endocrine therapy (ET) significantly improves invasive disease-free survival (iDFS). This groundbreaking research, presented at the 2025 ASCO Annual Meeting, offers a new avenue for patients seeking to reduce the risk of recurrence.
Dalpiciclib: A New Hope for Early Breast Cancer
The DAWNA-A trial focused on evaluating dalpiciclib, a CDK4/6 inhibitor, as an adjuvant treatment for HR+/HER2- early breast cancer. The study met its primary endpoint at the first internal analysis, showcasing a notable benefit for patients receiving dalpiciclib in combination with ET compared to those on placebo plus ET.
Key Findings from the DAWNA-A trial
At a median follow-up of 20.3 months, the results were compelling:
Superior iDFS: Patients treated with dalpiciclib plus ET achieved a statistically significant improvement in iDFS. The hazard ratio (HR) was 0.56 (95% CI 0.43-0.71), with a one-sided P-value less than .0001, indicating a significant reduction in the risk of invasive disease recurrence.
Consistent Benefits: These benefits were observed to be consistent across various patient subgroups,underscoring the broad applicability of this treatment approach.
Improved DFS and Distant DFS: The combination of dalpiciclib and ET also demonstrated superior performance in terms of overall disease-free survival (DFS) and distant disease-free survival (DDS) when compared to the placebo group.
Zhi-Ming Shao, PhD, from Fudan University Shanghai Cancer Center, who presented the findings, stated, “The phase III DAWNA-A met its primary end point at the first internal analysis, with significant iDFS benefits with dalpiciclib plus [ET] versus placebo plus [ET].”
Safety and Tolerability Profile
A crucial aspect of any new cancer treatment is its safety profile. The DAWNA-A trial reported favorable safety outcomes for dalpiciclib in combination with ET.
No Treatment-Related Deaths: Importantly, there were no deaths attributed to treatment-related adverse events (TRAEs).
Manageable Adverse Events: Treatment-related adverse events occurred in 3.7% of patients in the dalpiciclib arm and 1.5% in the placebo arm. Discontinuation of treatment due to TRAEs was also low, occurring in 2.1% of patients in the dalpiciclib group and 0.8% in the placebo group.
These findings suggest that dalpiciclib can be integrated into adjuvant treatment regimens with a manageable and acceptable safety profile.
Implications for Clinical Practice
The results of the DAWNA-A trial have significant implications for the management of HR+/HER2- early breast cancer. Dalpiciclib, in combination with endocrine therapy, is emerging as a promising neoadjuvant treatment option, particularly for Chinese populations, as suggested by Dr. Shao. This advancement offers a new strategy to enhance treatment outcomes and reduce the likelihood of recurrence for patients diagnosed with this common form of breast cancer.
References:
- A study of SHR6390 in combination with fulvestrant in patients with HR positive and HER2 negative advanced breast cancer. Updated June 3,2021. Accessed July 11, 2025. https://clinicaltrials.gov/study/NCT03927456
- New CDK4/6 Inhibitor offers benefits for advanced-stage, hormone receptor-positive, HER2-negative breast cancer. breastcancer